

1. Taylor F, Huffman MD, Macedo AF, Moore THM, Burke M, Davey Smith G, Ward K, Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews. 2013; Issue 1. Art. No.: CD004816.
2. Tonelli, M., Lloyd, A., Clement, F., Conly, J., Husereau, D., Hemmelgarn, B., Klarenbach, S., McAlister, F. A., Wiebe, N., & Manns, B. (2011). Efficacy of statins for primary prevention in people at low cardiovascular risk: A meta-analysis. CMAJ, 183(16), E1189–E1202.
3. Abramson J, Wright JM, Wilson PW, Murgo AJ, Nessel CC, Schiffman J. Should people at low risk of cardiovascular disease take a statin? BMJ. 2013;347
4. Anderson TJ, Grégoire J, Pearson GJ, et al. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Can J Cardiol. 2016;32(11):1263-1282.
5. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207.
6. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58
7. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J, ASTRONOMER Investigators. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: Results of the aortic stenosis progression observation: Measuring effects of rosuvastatin (Astronomer) trial. Circulation 2010;121(2):306-14
8. Chou R, Cantor A, Dana T, Wagner J, Ahmed AY, Fu R, Ferencik M. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2016;316(19):2008-2024.
9. Public Health Agency of Canada. Cardiovascular Disease Risk Assessment: Recommendations and Guidelines. *PHAC Guidelines*.
10. *Lipscombe, L., Booth, G., et al. (2018). Canadian Diabetes Association 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.*
11. Rabi, D. M., McBrien, K. A., et al. (2020). Hypertension Canada's 2020 Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children.